Multicentre Retrospective Cohort Study of Palliative Care Pathways in Patients Who Died From Sarcoma (SARCOPALL)

April 9, 2026 updated by: Centre Leon Berard

The goal of this observational study is to describe palliative pathways in adult patients who died from their sarcoma.

The main question it aims to answer is:

How patients who died from sarcoma are followed by palliative team.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

207

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lyon, France
        • Centre Leon Berard

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

All patients with sarcoma follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie who died in 2024

Description

Inclusion Criteria:

  • Oncology follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie
  • sarcoma histology confirmed
  • >18 years at diagnosis
  • death between 01/01/2024 ans 31/12/2024
  • death related to sarcoma

Exclusion Criteria:

  • >1 year between last follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie and death
  • patient opposed to the collect of data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
adult patients who died from sarcoma with >1 agressivness near the end of life criteria
adult patients who died from sarcoma with 0-1 agressivness near the end of life criteria

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Palliative pathways of patients who died from sarcoma
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 42 months

Palliative pathways will be described using the proportion of patients with each of the following component :

  • hospitalisation in a palliative care unit,
  • consultation with palliative care doctor,
  • mobile palliative care team advice We collect data on the first and last time of each kind of palliative follow up, we collect the number of day between the meeting and death For exemple: palliative care unit: first meeting 200 days before death and last meeting 80 days before death
From date of inclusion until the date of death from any cause, assessed up to 42 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment with chemotherapy in the last 14 days of life
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Percentage and number of patients having a treatment with chemotherapy in the last 14 days of life
From date of inclusion until the date of death from any cause, assessed up to 42 months
More than 1 visit in an emergency unit in the last 30 days of life
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Percentage and number of patients having more than 1 visit in an emergency unit in the last 30 days of life
From date of inclusion until the date of death from any cause, assessed up to 42 months
Hospitalization in a resuscitation unit in the last 30 days of life
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Percentage and number of patients having a hospitalization in a resuscitation unit in the last 30 days of life
From date of inclusion until the date of death from any cause, assessed up to 42 months
More than 1 hospitalization in the last 30 days of life
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Percentage and number of patients having more than 1 hospitalization in the last 30 days of life
From date of inclusion until the date of death from any cause, assessed up to 42 months
Less than 3 days in palliative care unit
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Percentage and number of patients having a hospitalization in a palliative care unit less than three days before death
From date of inclusion until the date of death from any cause, assessed up to 42 months
New chemotherapy regimen starting in the last 30 days of life
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 42 months
Percentage and number of patients having a new chemotherapy regimen starting in the last 30 days of life
From date of inclusion until the date of death from any cause, assessed up to 42 months
Place of death
Time Frame: At the date of death from any cause, assessed up to 42 months
Hospital and type of unit or home will be described
At the date of death from any cause, assessed up to 42 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Leon Berard

Collaborators

Gustave Roussy, Cancer Campus, Grand Paris
Institut Curie

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2024

Primary Completion (Actual)

December 31, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

March 25, 2026

First Submitted That Met QC Criteria

April 9, 2026

First Posted (Actual)

April 16, 2026

Study Record Updates

Last Update Posted (Actual)

April 16, 2026

Last Update Submitted That Met QC Criteria

April 9, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ET25-182 (SARCOPALL)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual Participant Data must not be shared according to the local regulation

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe